Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Shies Away From Zoom Meetings Because Of Security Concerns

Executive Summary

Uninvited guests already have accessed virtual meetings with sponsors using the application, raising concerns about the protection of proprietary information.

You may also be interested in...



FDA-Sponsor Interaction Could Increase Post-Pandemic With Virtual, In-Person Options

Scott Gottlieb says that some meetings should remain in-person, but with virtual options proven effective, the FDA could offer more opportunities to talk to sponsors.

PDUFA VII Communications: Earlier PMR Talks, Formal Meeting Additions

Sponsors will receive additional agency interactions through the formal meeting process, as well as an option to ask clarifying questions later.

Pondering The Future Of In-Person Meetings At The US FDA

Stakeholders believe virtual meetings should remain an option going forward, but that in-person sessions should still be convened in many cases.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel